<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762069</url>
  </required_header>
  <id_info>
    <org_study_id>CNS-201</org_study_id>
    <nct_id>NCT04762069</nct_id>
  </id_info>
  <brief_title>A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure of Standard First Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CNS Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CNS Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study.&#xD;
      Patients with GBM after failure of standard first line therapy will be randomized in a 2:1&#xD;
      ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will&#xD;
      include response and progression outcomes evaluated by a blinded central reviewer for each&#xD;
      patient according to RANO criteria.&#xD;
&#xD;
      A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50%&#xD;
      of all planned patients have completed the primary endpoint at 6 months. This review will&#xD;
      include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment&#xD;
      will not be paused during this interim analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Berubicin is one of the first anthracyclines that crosses the blood brain barrier and&#xD;
      overcomes drug resistance (i.e. it is not a substrate for multi-drug resistant/breast cancer&#xD;
      resistant transporters). A Phase 1 clinical trial of berubicin in patients with primary CNS&#xD;
      malignancies demonstrated a durable response (one subject alive 13+ years) as well as stable&#xD;
      disease in heavily pretreated patients. Therefore, this phase 2 study is designed to further&#xD;
      evaluate Berubicin's activity in patients with rGBM after treatment with standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-Label Study with a Randomized Control Arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Response and progression outcomes are evaluated by a blinded central reviewer for each patient according to RANO criteria</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>To assess the effect of berubicin compared with lomustine on overall survival (OS) in adult patients with GBM (WHO Grade IV) that has recurred after standard initial therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>To assess the effect of berubicin on progression free survival per Response Assessment in Neuro-Oncology (RANO) criteria in patients with GBM after failure of standard first line therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>To assess the effect of berubicin on event free survival (EFS) defined as the length of time from the initiation of study drug administration to disease progression, death, or discontinuation of treatment for any reason (eg, toxicity, intolerance, disease-related conditions, or failure to respond)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>To assess the effect of berubicin on overall response rates (ORR) in adult patients with GBM after failure of standard first line therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the Recommended Phase 2 Dose of Berubicin</measure>
    <time_frame>From signing of informed consent until until 28 days after the last dose of berubicin and 42 days after the last dose of lomustine, or until the patient receives any additional therapy for their disease (whichever comes first).</time_frame>
    <description>To assess the safety of the recommended Phase 2 dose of berubicin by the incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics Cmax</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>Maximum plasma concentration of Berubicin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics tmax</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>Time from each dose to reach the maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics AUC0-tau</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to Tau, where Tau is the dosing interval, calculated by the linear up/ linear down trapezoidal method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics AUC0-last</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration calculated by the linear up/log linear down trapezoidal method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics AUC0-∞</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to infinite time, calculated as the sum of AUC0-last and Clast/λz, where Clast is the last observed quantifiable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics t1/2</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>elimination half-life associated with the terminal slope (λz) of the log-linear drug concentration-time curve, calculated as ln(2)/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics CL</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>apparent total body clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics Vz</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics Css</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>Average concentration, calculated as the geometric mean of concentrations over the 72-hour dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics Rac</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>The accumulation ratio calculated as AUC0-tau (3rd dose) / AUC0-tau (1st dose)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Compare RANO to mRANO Criteria for Response and Progression Outcomes</measure>
    <time_frame>Through study completion an average of 4 years.</time_frame>
    <description>To compare RANO to modified RANO (m-RANO) criteria for response and progression outcomes for berubicin versus lomustine (an anthracycline versus an alkylating agent) for the treatment of adult patients with GBM after failure of standard first line therapy</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Glioblastoma Multiforme, Adult</condition>
  <arm_group>
    <arm_group_label>Berubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base as a 2 hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days)&#xD;
Each treatment cycle is 21 days. Subjects will be allowed to continue on treatment at the discretion of the Investigator if there is no evidence of disease progression and the subject is not experiencing unacceptable toxicity as well as if both the subject and Investigator agree that further therapy is in the subject's best interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lomustine (CCNU, CeeNU®, or Gleostine®) capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lomustine (CCNU, CeeNU®, or Gleostine®) capsules will be administered at the institutionally-approved dose and regimen or per the full prescribing information/summary of product characteristics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berubicin</intervention_name>
    <description>Berubicin HCl is a novel synthetic anthracycline with a chemical structure similar to doxorubicin HCl, a cytotoxic anthracycline topoisomerase II inhibitor isolated from cultures of Streptomyces peucetius var. caesius.</description>
    <arm_group_label>Berubicin</arm_group_label>
    <other_name>Berubicin Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>Lomustine is an anti-cancer (&quot;antineoplastic&quot; or &quot;cytotoxic&quot;) chemotherapy drug. This medication is classified as an &quot;alkylating agent.</description>
    <arm_group_label>Lomustine (CCNU, CeeNU®, or Gleostine®) capsules</arm_group_label>
    <other_name>Lomustine Capsules</other_name>
    <other_name>CCNU</other_name>
    <other_name>CeeNU</other_name>
    <other_name>Gleostine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients will be eligible for the study if they meet all of the following inclusion&#xD;
        criteria and none of the exclusion criteria.&#xD;
&#xD;
        Inclusion criteria&#xD;
&#xD;
          1. Written informed consent prior to any study-related procedure, and willing and able to&#xD;
             comply with the protocol and aware of the investigational nature of this study.&#xD;
&#xD;
          2. At least 18 years of age.&#xD;
&#xD;
          3. A confirmed GBM diagnosis must be based on local review of tumor tissue from the&#xD;
             initial biopsy, surgery, or re-resection. A formal pathology report confirming GBM is&#xD;
             acceptable. It is not a requirement for slides to be sent to a central reviewer.&#xD;
&#xD;
          4. Recurrent GBM as evaluated by RANO criteria, confirmed by central review, as follows:&#xD;
             Measurable disease is required with documented unequivocal evidence of tumor&#xD;
             recurrence or progression following prior therapy (ie, 25% increase in the sum of the&#xD;
             products of perpendicular diameters of the contrast-enhancing lesions while on stable&#xD;
             or increasing doses of corticosteroids) as documented by the investigator.&#xD;
&#xD;
          5. The tumor is localized supratentorially.&#xD;
&#xD;
          6. The lesion (or sum of lesions) does not exceed 50 cm3 in volume.&#xD;
&#xD;
          7. MGMT methylation status must be available; results of routinely used methods for MGMT&#xD;
             methylation testing (eg, methylation-specific polymerase chain reaction or&#xD;
             quantitative polymerase chain reaction) are acceptable.&#xD;
&#xD;
          8. No more than 1 prior line of treatment (eg, surgery followed by radiation with&#xD;
             concomitant chemotherapy, followed by adjuvant chemotherapy is considered as 1 line of&#xD;
             treatment). A second debulking surgery during the first line treatment is acceptable.&#xD;
             In addition, treatment with tumor treating fields (TTFields; Optune) is acceptable if&#xD;
             provided as first line therapy.&#xD;
&#xD;
          9. Recovery from toxicity/side effects of all prior therapy to Grade 1 or less, subject&#xD;
             to the investigator's discretion, except for alopecia; the following time intervals&#xD;
             from previous treatments are required to be eligible:&#xD;
&#xD;
               1. Twelve weeks from the completion of radiation (to reduce risk of&#xD;
                  pseudoprogression), unless progression is confirmed by biopsy&#xD;
&#xD;
               2. 4 weeks from the end of any previous chemotherapy or 6 weeks after the end of&#xD;
                  treatment with nitrosoureas&#xD;
&#xD;
               3. 4 weeks from the end of any TTFields treatment&#xD;
&#xD;
               4. 4 weeks from any major surgery (maximal debulking surgery, either gross total&#xD;
                  resection or partial resection) or significant traumatic injury, and any surgery&#xD;
                  incisions or wounds must be completely healed&#xD;
&#xD;
         10. A stable or decreasing dose of corticosteroids (or none) for brain edema for at least&#xD;
             5 days prior to baseline MRI and enrollment in the study.&#xD;
&#xD;
         11. Immunosuppressive therapies allowed include the use of topical, inhalational,&#xD;
             ophthalmic, or intra-articular glucocorticoids, or the use of physiologic replacement&#xD;
             doses of glucocorticoids.&#xD;
&#xD;
         12. Eligible for chemotherapy based on adequate bone marrow function and organ function&#xD;
             within 2 weeks of study treatment as defined by the following laboratory guidelines,&#xD;
             subject to the investigator's discretion:&#xD;
&#xD;
               1. Hematopoietic function: total white blood cell count ≥3000/mm³, absolute&#xD;
                  neutrophil count ≥1500/mm³, platelet count ≥75,000/mm³, hemoglobin ≥10 g/dL&#xD;
&#xD;
               2. Hepatic function: bilirubin ≤1.5 × the upper limit of normal (ULN) (excluding&#xD;
                  Gilberts Syndrome, for which bilirubin must be ≤4 × ULN); aspartate&#xD;
                  aminotransferase and alanine aminotransferase &lt;3 × ULN, and alkaline phosphatase&#xD;
                  ≤2.5 × ULN&#xD;
&#xD;
               3. Renal function: serum creatinine ≤1.5 × ULN or for patients with creatinine&#xD;
                  levels above the ULN, or estimated creatinine clearance of ≥60 mL/min/1.73 m2,&#xD;
                  calculated using the Cockcroft-Gault formula&#xD;
&#xD;
               4. Activated partial thromboplastin time ≤1.5 × ULN&#xD;
&#xD;
         13. Female patients of childbearing potential, and male study patients and their sexual&#xD;
             partners of childbearing potential must agree to practice a highly effective method of&#xD;
             contraception beginning at least 28 days before the start of treatment until at least&#xD;
             6 months after the last dose of study drug.&#xD;
&#xD;
               1. A woman of childbearing potential is defined as a woman who is not permanently&#xD;
                  sterilized or postmenopausal. Postmenopausal is defined as 12 months with no&#xD;
                  menses without an alternative medical cause.&#xD;
&#xD;
               2. Women of childbearing potential must have a negative serum or urine pregnancy&#xD;
                  test.&#xD;
&#xD;
               3. A highly effective method of birth control is defined as one which results in a&#xD;
                  low failure rate (ie, less than 1% per year) when used consistently and&#xD;
                  correctly, such as implants, injectables, combined oral contraceptives, some&#xD;
                  intrauterine devices, sexual abstinence, or vasectomized partner. For patients&#xD;
                  using a hormonal contraceptive method, information regarding all medications&#xD;
                  being administered to the patient and their potential effect on the contraceptive&#xD;
                  should be addressed.&#xD;
&#xD;
         14. Patients with prior malignancies must be disease-free for ≥5 years. However,&#xD;
             curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ&#xD;
             of the cervix, breast, or bladder; or prostate cancer curatively treated at the time&#xD;
             of screening is allowed.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Unable or not willing to comply with the protocol regulations.&#xD;
&#xD;
          2. Any additional concurrent radiation therapy or chemotherapy (including but not limited&#xD;
             to temozolomide) for recurrent or progressive GBM after a first line treatment.&#xD;
&#xD;
          3. Prior treatment with bevacizumab.&#xD;
&#xD;
          4. Prior treatment with lomustine.&#xD;
&#xD;
          5. Screening MRI showing a mass effect defined as significant compression of the&#xD;
             ventricular system and/or a midline shift (≥10 mm, central MRI review).&#xD;
&#xD;
          6. Any condition (medical, social, psychological) that would prevent adequate information&#xD;
             and follow-up, including but not limited to clinically relevant psychiatric disorders,&#xD;
             legal incapacity, dementia, or altered mental status.&#xD;
&#xD;
          7. Presence of poorly controlled seizures, defined as occurring despite SOC or requiring&#xD;
             hospitalization.&#xD;
&#xD;
          8. Prior anthracycline cumulative dose more than 550 mg/m2.&#xD;
&#xD;
          9. Heart disease:&#xD;
&#xD;
               1. LVEF &lt;50%&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
               3. Congestive heart failure with New York Heart Association classification of 3 or 4&#xD;
&#xD;
               4. Patients with baseline QT/QTc interval &gt;480 msec, a history of additional risk&#xD;
                  factors for torsades de pointes (eg, heart failure, hypokalemia, family history&#xD;
                  of long QT syndrome) and using concomitant medications that significantly prolong&#xD;
                  the QT/QTc interval&#xD;
&#xD;
               5. History of myocardial infarction within 12 months of enrollment&#xD;
&#xD;
         10. Uncontrolled hypertension (systolic blood pressure [BP] &gt;150 mmHg and/or diastolic BP&#xD;
             &gt;100 mmHg).&#xD;
&#xD;
         11. Known to be positive for hepatitis B virus surface antigen (HBsAg), hepatitis C virus&#xD;
             (HCV), human immunodeficiency virus (HIV), COVID-19 (currently positive at time of&#xD;
             screening), or any other acute viral, bacterial, or fungal infection (testing not&#xD;
             required unless symptomatic or suspected disease).&#xD;
&#xD;
         12. Any other uncontrolled intercurrent medical conditions, including but not limited to&#xD;
             diabetes mellitus or chronic obstructive pulmonary disease that have not been well&#xD;
             controlled by medical management over the prior 3 months are ineligible unless&#xD;
             approved by the sponsor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Silberman, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CNS Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zena Muzyczenko</last_name>
    <phone>800-946-9185</phone>
    <email>clinicaltrials@cnspharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brittany Maykowski</last_name>
    </contact>
    <investigator>
      <last_name>Ekokobe Fonkem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Masci</last_name>
    </contact>
    <investigator>
      <last_name>Maciej Mrugala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California Permanente Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Bolden</last_name>
    </contact>
    <investigator>
      <last_name>Richard Green, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manisha Dandekar</last_name>
    </contact>
    <investigator>
      <last_name>Daniela Bota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Califonia San Diego Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lara Rose</last_name>
    </contact>
    <investigator>
      <last_name>David Piccioni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Cai</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Butowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint John's Cancer Institute at Providence Saint John's Health Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mini Gill</last_name>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Healthcare Research Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melina Rye, MS</last_name>
    </contact>
    <investigator>
      <last_name>Michael Pearlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ewa Szymkiewicz</last_name>
    </contact>
    <investigator>
      <last_name>Kurt Jaeckle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dionne Jean</last_name>
    </contact>
    <investigator>
      <last_name>Erin Dunbar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Praneeth Chebrolu</last_name>
    </contact>
    <investigator>
      <last_name>Joo Yeon Nam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Rice</last_name>
    </contact>
    <investigator>
      <last_name>John Villano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Meher Davara</last_name>
    </contact>
    <investigator>
      <last_name>Christopher Trevino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anicka Samuel</last_name>
    </contact>
    <investigator>
      <last_name>Suriya Jeyapalan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicole Sando</last_name>
    </contact>
    <investigator>
      <last_name>Elizabeth Neil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>550905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carol Szumlanski</last_name>
    </contact>
    <investigator>
      <last_name>Sani Kizilbash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Metzger</last_name>
    </contact>
    <investigator>
      <last_name>Shahzad Raza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Vidlak</last_name>
    </contact>
    <investigator>
      <last_name>Nicole Shonka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Cappello</last_name>
    </contact>
    <investigator>
      <last_name>Samuel Goldlust, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Traci Saunders</last_name>
    </contact>
    <investigator>
      <last_name>Michael Salacz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Healthcare</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrice Light</last_name>
    </contact>
    <investigator>
      <last_name>Robert Aiken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Kaufman</last_name>
    </contact>
    <investigator>
      <last_name>Ajay Abad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Singh</last_name>
    </contact>
    <investigator>
      <last_name>Howard Fine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stevie Threatt</last_name>
    </contact>
    <investigator>
      <last_name>Mustafa Khasraw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Jewell</last_name>
    </contact>
    <investigator>
      <last_name>Shirley Ong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riley Roth-Carter</last_name>
    </contact>
    <investigator>
      <last_name>Prakash Ambady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Stanley</last_name>
    </contact>
    <investigator>
      <last_name>Michael Glantz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Schultz</last_name>
    </contact>
    <investigator>
      <last_name>Jon Glass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Cancer Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arun Venugopal</last_name>
    </contact>
    <investigator>
      <last_name>George Bobustuc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology PA</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisca Fernandez</last_name>
    </contact>
    <investigator>
      <last_name>Brian Vaillant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joyce Ghormley</last_name>
    </contact>
    <investigator>
      <last_name>Karen Fink, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Guerra</last_name>
    </contact>
    <investigator>
      <last_name>Jay-Jiguang Zhu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Kingsford</last_name>
    </contact>
    <investigator>
      <last_name>Howard Colman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caryl Tongco</last_name>
    </contact>
    <investigator>
      <last_name>Kester Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Brain Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study data will be shared with WPD Pharmaceuticals, Inc., sub-licensee of Berubicin.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

